Dasatinib Holiday for Improved Tolerability

Phase 3 Completed 291 enrolled University of Jena

RandomizedParallel-groupOpen-labelTreatment

Summary

Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line) (DasaHIT Trial (Dasatinib Holiday for Improved Tolerability))

Timeline

Start: 2016-08
Primary completion: 2023-03-31
Completion: 2023-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dasatinib anhydrous	Small molecule	100 mg	—

Dasatinib Holiday for Improved Tolerability

Summary

Timeline

Drugs

Indications